Archive for November 2017
Basilea Snags Extended $226M+ Antifungal Deal With Pfizer
Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales. Source: BioSpace
Read MoreTexas Compounder Warned for Sterility Practices, Other GMP Violations
The FDA issued a warning letter to a Texas drug compounding facility after it failed to resolve problems identified during an inspection, including serious deficiencies in sterile drug processing. Source: Drug Industry Daily
Read MoreDr. Reddy’s Hit With Class-Action Suit Claiming False Statements
Dr. Reddy’s Laboratories said it will contest a class-action lawsuit by investors who claim the company made false or misleading statements about its quality system. Source: Drug Industry Daily
Read MoreGottlieb Provides Update One Year after the Cures Act
As research advances into the biological underpinnings of diseases such as cancer, the FDA is expecting to see more drugs providing more data demonstrating survival benefit earlier in product development, Commissioner Scott Gottlieb told lawmakers at a one-year follow-up hearing on the 21st Century Cures Act. Source: Drug Industry Daily
Read More3 Bioeconomy Stocks Investors Should Not Hesitate to Buy
While the words biotech and biopharma are often used interchangeably, they aren’t the same thing – not even close, in fact. Source: BioSpace
Read MoreSexual Harassment Scandals Hit Novartis and Pfizer's Korea Units
On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September. Source: BioSpace
Read MoreBoston's Anti-Aging Startup resTORbio Scores $40M
This financing brings the total capital raised this year to $65 million, including a $25 million Series A financing that was completed earlier this year. Source: BioSpace
Read MoreSanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow
Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace
Read MoreGenmab and Johnson & Johnson Rake in the Bucks Together, Sparking Takeover Speculation
Genmab just received a $20M milestone payment from Janssen Biotech. Source: BioSpace
Read MoreCambridge's Semma Therapeutics Lands $114M for Novel Diabetes Quest
The round was co-led by Eight Roads Ventures and Cowen Healthcare Investments. Source: BioSpace
Read More